#SOHO25

Dr Ashwin Kishtagari’s Top 4 Picks From SOHO 2025 Ashwin Kishtagari, MD, shares his top 4 picks from the abstracts presented at the 13th annual meeting of the Society of Hematologic Oncology.

Dr Ashwin Kishtagari (@ashkishtaagri.bsky.social) of @vumedicine.bsky.social shares his top picks from #SOHO2025. #SOHO25 Read about them here:
www.cancertherapyadvisor.com/features/soh...

Predictors of cGVHD Outcomes Remain Elusive in Pediatric Hematologic Malignancies | OncLive Acute GVHD was shown to be a risk factor for chronic GVHD, but factors such as organ involvement showed no correlation with long-term outcomes.

Predictors of cGVHD Outcomes Remain Elusive in Pediatric Hematologic Malignancies
#SOHO25 #hematology #GVHD
www.onclive.com/view/predict...

BTK Inhibitors Lead to Decreased Health Care Resource Utilization in MCL | OncLive BTK inhibitors were associated with lower health care resource utilization vs other regimens in mantle cell lymphoma.

BTK Inhibitors Lead to Decreased Health Care Resource Utilization in MCL #SOHO25 #hematology #MCL www.onclive.com/view/btk-inh...

Bexobrutideg Shows Early Promise in BTK- and BCL2-Exposed, Relapsed/Refractory CLL The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.

Bexobrutideg Shows Early Promise in BTK- and BCL2-Exposed, Relapsed/Refractory CLL #SOHO25 #CLL
www.onclive.com/view/bexobru...

Pictured here is Dr. Christopher Flowers, Blood Cancer Discovery Scientific Editor, who featured the “Microenvironment Characteristics of Follicular Lymphoma” study as a future approach to guiding therapy selection. Read the article: buff.ly/OBictLV #SOHO25

SC Daratumumab Prolongs PFS in High-Risk Smoldering Myeloma Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

SC Daratumumab Prolongs PFS in High-Risk Smoldering Myeloma
@societyofhemonc.bsky.social #SOHO25 #mmsm
www.onclive.com/view/sc-dara...

Ziftomenib With 7+3 Shows Early Promise in Newly Diagnosed NPM1-Mutated/KMT2A-Rearranged AML The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Ziftomenib With 7+3 Shows Early Promise in Newly Diagnosed NPM1-Mutated/KMT2A-Rearranged AML
@yalecancer.bsky.social @societyofhemonc.bsky.social #AML #SOHO25
www.onclive.com/view/ziftome...

Peak CAR T-Cell Expansion Associated With Reduced Relapse Risk Following Brexu-Cel Consolidation in B-ALL Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

Peak CAR T-Cell Expansion Associated With Reduced Relapse Risk Following Brexu-Cel Consolidation in B-ALL @mdanderson.bsky.social
@societyofhemonc.bsky.social
#SOHO25 #hematology #ALL
www.onclive.com/view/peak-ca...

Olutasidenib Monotherapy Yields Responses in Primary Refractory IDH1-Mutant AML A post hoc analysis demonstrated the efficacy of olutasidenib monotherapy in primary refractory patients with IDH1-mutant AML.

Olutasidenib Monotherapy Yields Responses in Primary Refractory IDH1-Mutant AML
#AML #SOHO25
www.onclive.com/view/olutasi...